Controlling the biological function of calcium phosphate bone substitutes with drugs
Source abstract
Abstract
There is a growing interest in bone tissue engineering for bone repair after traumatic, surgical or pathological injury, such as osteolytic tumor or osteoporosis. In this regard, calcium phosphate (CaP) bone substitutes have been used extensively as bone-targeting drug-delivery systems. This localized approach improves the osteogenic potential of bone substitutes by delivering bone growth factors, thus extending their biofunctionality to any pathological context, including infection, irradiation, tumor and osteoporosis. This review briefly describes the physical and chemical processes implicated in the preparation of drug-delivering CaPs. It also describes the impact of these processes on the intrinsic properties of CaPs, especially in terms of the drug-release profile. In addition, this review focuses on the potential influence of drugs on the resorption rate of CaPs. Interestingly, by modulating the resorption parameters of CaP biomaterials, it should be possible to control the release of bone-stimulating ions, such as inorganic phosphate, in the vicinity of bone cells. Finally, recent in vitro and in vivo evaluations are extensively reported.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Bone Tissue Engineering Materials · Bone health and treatments · Bone Metabolism and Diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Bone graft substitutes: osteobiologics10.1016/j.cpm.2005.07.004 ↗
2. Calcium phosphate biomaterials as bone drug delivery systems: a review10.1016/j.drudis.2010.05.003 ↗
3. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women10.1007/s00198-007-0506-x ↗
4. Calcium phosphate materials in restorative dentistry: a review10.1177/08959374880020011101 ↗
5. Biomechanical evaluation of kyphoplasty and vertebroplasty with calcium phosphate cement in a simulated osteoporotic compression fracture10.1007/s007760300032 ↗
6. Use of injectable calcium-phosphate cement for the fixation of titanium implants: an experimental study in goats10.1002/jbm.b.10039 ↗
7. Histological evaluation of the bone response to calcium phosphate cement implanted in cortical bone10.1016/S0142-9612(02)00438-6 ↗
8. Experimental tibial plateau fractures augmented with calcium phosphate cement or autologous bone graft10.2106/00004623-200302000-00007 ↗
9. Osseous integration of calcium phosphate in osteoporotic vertebral fractures after kyphoplasty: initial results from a clinical and experimental pilot study10.1007/s00198-006-0128-8 ↗
10. LeGeros RZ. Calcium phosphate in oral biology and medicine. Monographs in oral sciences, vol. 15; 1991.
11. Biodegradation and bioresorption of calcium phosphate ceramics10.1016/0267-6605(93)90049-D ↗
12. Macroporous biphasic calcium phosphate ceramics: influence of macropore diameter and macroporosity percentage on bone ingrowth10.1016/S0142-9612(97)00180-4 ↗
13. A new technological procedure using sucrose as porogen compound to manufacture porous biphasic calcium phosphate ceramics of appropriate micro- and macrostructure10.1016/j.ceramint.2009.07.001 ↗
14. Significance of the porosity and physical chemistry of calcium phosphate ceramics. Biodegradation–bioresorption10.1111/j.1749-6632.1988.tb38519.x ↗
15. Macroporous biphasic calcium phosphate ceramics: influence of five synthesis parameters on compressive strength10.1002/(SICI)1097-4636(199612)32:4<603::AID-JBM13>3.0.CO;2-E ↗
16. Apatitic calcium phosphates: possible dental restorative materials
17. Effects of neutral salts in a bench-scale caries model10.1177/00220345860650090201 ↗
18. Calcium phosphate cements as bone drug delivery systems: a review10.1016/j.jconrel.2006.04.007 ↗
19. New processing approaches in calcium phosphate cements and their applications in regenerative medicine10.1016/j.actbio.2010.01.036 ↗
20. Transmission electron microscopic study on setting mechanism of tetracalcium phosphate/dicalcium phosphate anhydrous-based calcium phosphate cement10.1002/jbm.a.10250 ↗
21. Self-hardening calcium deficient hydroxyapatite/gelatine foams for bone regeneration10.1007/s10856-009-3918-7 ↗
22. Physico-chemical–mechanical and in vitro biological properties of calcium phosphate cements with doped amorphous calcium phosphates10.1016/j.biomaterials.2006.10.018 ↗
23. Calcium phosphate cement containing resorbable fibers for short-term reinforcement and macroporosity10.1016/S0142-9612(01)00095-3 ↗
24. Fabrication and mechanical properties of calcium phosphate cements (CPC) for bone substitution10.1016/j.msec.2010.10.014 ↗
25. Klijn RJ, van den Beucken JJ, Felix Lanao RP, Veldhuis G, Leeuwenburgh SC, Wolke JG, et al. Three different strategies to obtain porous calcium phosphate cements: comparison of performance in a rat skull bone augmentation model. Tissue Eng Part A 2012.10.1089/ten.tea.2011.0444 ↗
26. Ginebra MP, Canal C, Espanol M, Pastorino D, Montufar EB. Calcium phosphate cements as drug delivery materials. Adv Drug Deliv Rev 2012.10.1016/j.addr.2012.01.008 ↗
27. Intrinsic porosity of calcium phosphate cements and its significance for drug delivery and tissue engineering applications10.1016/j.actbio.2009.03.011 ↗
28. Calcium phosphate ceramics as bone drug-combined devices10.4028/www.scientific.net/KEM.441.181 ↗
29. Analgesic properties of calcium phosphate apatite loaded with bupivacaine on postoperative pain10.1002/jbm.b.31628 ↗
30. Development of porous apatite ceramic for local delivery of chemotherapeutic agents10.1002/(SICI)1097-4636(19980315)39:4<536::AID-JBM5>3.0.CO;2-K ↗
31. Isostatic compression, a new process for incorporating vancomycin into biphasic calcium phosphate: comparison with a classical method10.1016/S0142-9612(99)00139-8 ↗
32. Association of vancomycin and calcium phosphate by dynamic compaction: in vitro characterization and microbiological activity10.1016/S0142-9612(00)00436-1 ↗
33. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and beta-tricalcium phosphate in a rabbit model10.1097/01.brs.0000172155.17239.fa ↗
34. VEGF incorporated into calcium phosphate ceramics promotes vascularisation and bone formation in vivo10.22203/eCM.v019a04 ↗
35. Healing of acute alveolar bone dehiscence following treatment with porous biphasic calcium phosphate in beagle dogs10.1007/s00784-010-0454-2 ↗
36. Intraosseous delivery of paclitaxel-loaded hydroxyapatitealginate composite beads delaying paralysis caused by metastatic spine cancer in rats10.3171/SPI.2008.9.11.502 ↗
37. Understanding the influence of MgO and SrO binary doping on the mechanical and biological properties of beta-TCP ceramics10.1016/j.actbio.2010.05.012 ↗
38. Ionic substitutions in calcium phosphates synthesized at low temperature10.1016/j.actbio.2009.12.041 ↗
39. Characterization and properties of novel gallium-doped calcium phosphate ceramics10.1021/ic2007777 ↗
40. Synthesis and structural characterization of strontium- and magnesium-co-substituted beta-tricalcium phosphate10.1016/j.actbio.2009.08.009 ↗
41. Preparation and preliminary cytocompatibility of magnesium doped apatite cement with degradability for bone regeneration10.1007/s10856-011-4228-4 ↗
42. Development of a strontium-containing hydroxyapatite bone cement10.1016/j.biomaterials.2004.10.032 ↗
43. Silicon-stabilized alpha-tricalcium phosphate and its use in a calcium phosphate cement: characterization and cell response10.1016/j.actbio.2011.11.021 ↗
44. Silicon-substituted calcium phosphates—a critical view10.1016/j.biomaterials.2009.08.007 ↗
45. Synthesis, mechanical and biological characterization of ionic doped carbonated hydroxyapatite/beta-tricalcium phosphate mixtures10.1016/j.actbio.2010.12.009 ↗
46. Injectability of brushite-forming Mg-substituted and Sr-substituted alpha-TCP bone cements10.1007/s10856-009-3890-2 ↗
47. Hybrid materials applied to biotechnologies: coating of calcium phosphates for the design of implants active against bone resorption10.1039/b503680a ↗
48. Control of gentamicin release from a calcium phosphate cement by admixed poly(acrylic acid)10.1002/1520-6017(200010)89:10<1262::AID-JPS4>3.0.CO;2-7 ↗
49. Alendronate and Pamidronate calcium phosphate bone cements: setting properties and in vitro response of osteoblast and osteoclast cells10.1016/j.jinorgbio.2008.09.012 ↗
50. Transforming growth factor-beta1 incorporation in a calcium phosphate bone cement: material properties and release characteristics10.1002/jbm.1241 ↗
51. Silver-doped calcium phosphate cements with antimicrobial activity10.1016/j.actbio.2011.06.049 ↗
52. Effects of added antibiotics on the basic properties of anti-washout-type fast-setting calcium phosphate cement10.1002/(SICI)1097-4636(199802)39:2<308::AID-JBM19>3.0.CO;2-8 ↗
53. Setting characteristics and mechanical behaviour of a calcium phosphate bone cement containing tetracycline10.1016/S0142-9612(00)00252-0 ↗
54. Gentamicin-loaded hydraulic calcium phosphate bone cement as antibiotic delivery system10.1021/js960405a ↗
55. The biodegradation mechanism of calcium phosphate biomaterials in bone10.1002/jbm.10259 ↗
56. Resorption patterns of calcium-phosphate cements in bone10.1002/jbm.a.10593 ↗
57. Passive and active in vitro resorption of calcium and magnesium phosphate cements by osteoclastic cells10.1089/ten.tea.2010.0281 ↗
58. In vitro biodegradation of three brushite calcium phosphate cements by a macrophage cell-line10.1016/j.biomaterials.2006.04.030 ↗
59. Biocompatibility and resorption of a brushite calcium phosphate cement10.1016/j.biomaterials.2004.11.056 ↗
60. Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth10.1097/00001665-200305000-00007 ↗
61. Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo10.2174/156720109787846225 ↗
62. Porous tricalcium phosphate and transforming growth factor used for anterior spine surgery10.1007/s005860100325 ↗
63. The effects of inorganic additives to calcium phosphate on in vitro behavior of osteoblasts and osteoclasts10.1016/j.biomaterials.2010.01.002 ↗
64. Differentiation and activity of human preosteoclasts on chitosan enriched calcium phosphate cement10.1016/j.biomaterials.2009.04.044 ↗
65. Fast setting calcium phosphate cement–chitosan composite: mechanical properties and dissolution rates10.1177/0885328206063687 ↗
66. Osteoclastic cell behaviors affected by the a-tricalcium phosphate based bone cements
67. Osteoblast autonomous Pi regulation via Pit1 plays a role in bone mineralization10.1128/MCB.00104-07 ↗
68. The emergence of phosphate as a specific signaling molecule in bone and other cell types in mammals10.1007/s00018-010-0527-z ↗
69. Phosphate stimulates matrix Gla protein expression in chondrocytes through the extracellular signal regulated kinase signaling pathway10.1210/en.2006-0763 ↗
70. Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium10.1016/j.bone.2010.12.002 ↗
71. Collagen biomineralization in vivo by sustained release of inorganic phosphate ions10.1002/adma.200902778 ↗
72. A novel skeletal drug delivery system using a self-setting calcium phosphate cement. 5. Drug release behavior from a heterogeneous drug-loaded cement containing an anticancer drug10.1002/jps.2600831109 ↗
73. Effect of geometrical cement size on in vitro and in vivo indomethacin release from self-setting apatite cement10.1016/S0168-3659(97)00264-2 ↗
74. Calcium-level responsive controlled drug delivery from implant dosage forms to treat osteoporosis in an animal model10.1016/S0169-409X(00)00065-X ↗
75. Rate of release of medicaments from ointment bases containing drugs in suspension10.1002/jps.2600501018 ↗
76. Mechanism of sustained action medication: theoretical analysis of rate of release of solid drugs dispersed in solid matrices10.1002/jps.2600521210 ↗
77. Effect of geometrical structure on drug release rate of a three-dimensionally perforated porous apatite/collagen composite cement10.1002/jps.21835 ↗
78. In vitro characterisation of calcium phosphate biomaterials loaded with lidocaine hydrochloride and morphine hydrochloride10.1007/s10856-010-4172-8 ↗
79. In vitro characterization of calcium phosphate biomaterial loaded with linezolid for osseous bone defect implantation10.1177/0885328210381535 ↗
80. Inactivation of Staphylococcus aureus in calcium phosphate biomaterials via isostatic compression10.1002/jbm.b.31408 ↗
81. Doxycycline sustained release from brushite cements for the treatment of periodontal diseases10.1002/jbm.a.31610 ↗
82. In vitro gentamicin release from commercially available calcium-phosphate bone substitutes influence of carrier type on duration of the release profile10.1186/1471-2474-7-18 ↗
83. Protein-based signaling systems in tissue engineering10.1016/j.copbio.2003.08.004 ↗
84. Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A10.1210/en.143.4.1545 ↗
85. Analysis of the roles of microporosity and BMP-2 on multiple measures of bone regeneration and healing in calcium phosphate scaffolds10.1016/j.actbio.2010.12.030 ↗
86. Bone inductive properties of rhBMP-2 loaded porous calcium phosphate cement implants in cranial defects in rabbits10.1016/j.biomaterials.2003.09.007 ↗
87. Closure of rabbit calvarial critical-sized defects using protective composite allogeneic and alloplastic bone substitutes10.1097/01.scs.0000230615.49270.d1 ↗
88. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate model10.2106/00004623-200409000-00015 ↗
89. RhBMP-2 delivered in a calcium phosphate cement accelerates bridging of critical-sized defects in rabbit radii10.2106/JBJS.E.01006 ↗
90. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft10.1097/01.brs.0000240715.78657.81 ↗
91. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies10.1097/00007632-200212010-00005 ↗
92. VEGF improves, whereas sFlt1 inhibits, BMP2-induced bone formation and bone healing through modulation of angiogenesis10.1359/JBMR.050708 ↗
93. Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ10.1002/jgm.287 ↗
94. Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration10.1016/j.biomaterials.2009.01.031 ↗
95. In vitro and in vivo release of vascular endothelial growth factor from gelatin microparticles and biodegradable composite scaffolds10.1007/s11095-008-9685-1 ↗
96. The effect of combined delivery of recombinant human bone morphogenetic protein-2 and recombinant human vascular endothelial growth factor 165 from biomimetic calcium-phosphate-coated implants on osseointegration10.1111/j.1600-0501.2010.02133.x ↗
97. Locally delivered rhTGF-beta2 enhances bone ingrowth and bone regeneration at local and remote sites of skeletal injury10.1016/S0736-0266(00)00015-2 ↗
98. Transforming growth factor-beta1 incorporated in calcium phosphate cement stimulates osteotransductivity in rat calvarial bone defects10.1034/j.1600-0501.2001.120609.x ↗
99. Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration10.1007/s11095-005-4589-9 ↗
100. A preliminary study on the enhancement of the osteointegration of a novel synthetic hydroxyapatite scaffold in vivo10.1002/jbm.a.10564 ↗